Track topics on Twitter Track topics that are important to you
Consumer awareness in personalized medicine grows to 33% in 2019, but more education is needed to inform patients on the improvements in care it can bring.
SAN FRANCISCO (PRWEB) April 30, 2019
Dosis, an AI-powered personalized dosing platform, and the developer of the Strategic Anemia Advisor (SAA) decision support tool, today released findings from the 2019 Dosis Personalized and Digital Medicine Consumer Report. The report surveyed more than 1,000 consumers, weighted for the U.S. population, to gain a better understanding of how big the disconnect is between the advances in personalized medicine approaches and general consumer awareness of its benefits.
While the report found awareness of personalized medicine has risen to 33% in 2019, the progress with educating patients on the improvements in care that it can bring, along with the treatments associated with its practice, continues to be slow. In fact, consumer awareness has only grown by around 1% year-over-year since 2013.
Highlights from the 2019 Dosis Personalized and Digital Medicine Consumer Report include:
“As more consumers are educated on how their genetic makeup, lifestyle and environmental factors uniquely affect their medical treatments, I believe both awareness of and interest in personalized medicine will continue to grow,” said Shivrat Chhabra, Founder & CEO of Dosis. “Younger patients have expressed growing dissatisfaction with traditional care, and the findings of our report indicate that their interest in technology may be a major opportunity to further their awareness in personalized medicine alternatives.”
The full report is available here.
Dosis, an AI-powered personalized dosing platform, is the developer of the Strategic Anemia Advisor (SAA) clinical decision support tool. SAA is currently revolutionizing anemia management for more than 5,000 dialysis patients at more than 50 dialysis clinics across the country by supporting healthcare providers with determining a patient’s unique response to erythropoietin-stimulating agents (ESA) and recommending personalized dosages that keep individual patients within their hemoglobin target ranges. Dosis is headquartered in San Francisco. For more information, visit dosisinc.com.
For the original version on PRWeb visit: https://www.prweb.com/releases/dosis_releases_personalized_and_digital_medicine_consumer_report/prweb16275224.htmNEXT ARTICLE
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells. In vertebrates, it is composed of blo...
BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...